Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab safety and tolerability study in wet AMD patients with poor visual acuity and/or second affected eye
2013-003333-15Phase 4Completed
- Sponsor
- Novartis
- Start
- Sep 2013
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ranibizumab in exudative macular degeneration, sponsored by Novartis. Primary endpoint: Annual incidence of ocular and systemic drug-related adverse events. Started Sep 2013; status: completed.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2013-003333-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003333-15.